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Auditory verbal hallucinations (AVHs) are known as a core symptom of schizophrenia, but also occur in a number of other
conditions, not least in neurodegenerative disorders such as dementia. In the last decades, Transcranial Magnetic Stimulation
(TMS) emerged as a valuable therapeutic approach towards several neurological and psychiatric diseases, including AVHs. Herein
we report a case of a seventy-six-years-old woman with vascular-degenerative brain disease, complaining of threatening AVHs.The
patientwas treatedwith a high-frequency temporoparietal (T3P3) rTMSprotocol for fifteen days. A considerable reduction ofAVHs
in frequency and content (no more threatening) was observed. Although further research is needed, this seems an encouraging
result.
1. Introduction
Transcranial Magnetic Stimulation (TMS) is a noninvasive
technique of neuromodulation and neurostimulation based
on the principle of electromagnetic induction of an electric
field in the brain. It was originally developed for the of study
brain function [1]. Since Barker and colleagues first demon-
strated TMS, it has been widely used earlier to investigate
motor conduction and control, later in the study of cognitive
functions and brain plasticity. TMS is widely studied in
the diagnosis and treatment of neurological and psychiatric
diseases, too.
A hallucination is often referred to as “a sensory experi-
ence, which occurs in the absence of corresponding external
stimulation of the relevant sensory organ, has a sufficient
sense of reality to resemble a veridical perception, over
which the subject does not feel s/he has direct and voluntary
control and which occurs in the awake state” [2]. Auditory
verbal hallucinations (AVHs) are defined as perceptions
of speech without actual auditory stimulation and repre-
sent one of the most common hallucinatory experience,
which are a characteristic symptom of schizophrenia [3]
but also occur in a wealth of conditions, both neurolog-
ical/neurodegenerative (e.g., epilepsy, Alzheimer’s disease,
Parkinson’s disease, dementia, and hearing impairment) or
psychiatric (e.g., dissociative disorders, mood disorders, and
borderline personality disorder).
2. TMS and Auditory Hallucinations
Hoffman and colleagues [4] published the first report demon-
strating a reduction in auditory verbal hallucinations (AVHs)
after a low-frequency (1Hz) rTMS treatment to the posterior
superior temporal gyrus (STG). This brain area and, overall,
the temporoparietal cortex (TPC) are involved in speech
perception [5, 6] and are active during auditory hallucina-
tions [7–9]. After the publication by Hoffman and colleagues,
a number of studies replicated the positive findings using
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Table 1: Previous rTMS for AVHs studies.
Study 𝑁 active 𝑁 sham Stimulated Area Frequency % MT Session
Hoffman et al. [44] 12 12 T3P3 1Hz 80 4
McIntosh et al. [45] 16 16 T3P3 1Hz 80 4
Scho¨nfeldt-Lecuona et al. [46] 11 10 STG 1Hz 90 5
Chibbaro et al. [47] 8 8 T3P3 1Hz 90 4
Fitzgerald et al. [48] 17 15 T3P3 1Hz 90 10
Hoffman et al. [49] 27 23 T3P3 1Hz 90 10
Lee et al. [50] 13 14 T3P3 1Hz 100 10
Lee et al. [50] 12 14 T4P4 1Hz 100 10
Poulet et al. [51] 10 10 T3P3 1Hz 90 5
Brunelin et al. [52] 14 10 T3P3 1Hz 90 10
Jandl et al. [53] 16 16 T3P3 T4P4 1Hz 100 5
Jandl et al. [53] 16 16 T4P4 1Hz 100 5
Rosa et al. [54] 6 5 T3P3 1Hz 90 10
Saba et al. [55] 8 8 T3P3 1Hz 80 10
Vercammen et al. [56] 16 16 T3P3 1Hz 90 12
Vercammen et al. [56] 14 16 T3P3 T4P4 1Hz 90 12
Loo et al. [57] 18 18 T3P3 1Hz 110 3
Loo et al. [57] 18 18 T4P4 1Hz 110 3
Slotema et al. [58] 22 20 T3P3 1Hz 90 15
Slotema et al. [59] 20 20 fMRI 1Hz 90 15
MT: motor threshold; T3P3: left temporoparietal cortex; T4P4: right temporoparietal cortex; STG: superior temporal gyrus; fMRI: functional magnetic
resonance imaging.
this rTMS protocol (for a complete review see Table 1), and,
additionally, several meta-analyses supported the usefulness
of rTMS in the treatment of hallucinations [10–12]. Most
studies examined AVHs in schizophrenia, while there’s a lack
of studies about TMS to treat hallucinations in dementia,
even though a number of studies reported the presence of
psychotic symptoms (mostly delusions and hallucinations)
in Alzheimer’s and Parkinson’s diseases (for a more detailed
review see [13, 14]).
3. RDOCs and Circuitries Involved
Though the exact pathophysiological mechanisms of AVHs
remain actually unclear, neuroimaging studies have shown
abnormalities in a distributed network of brain regions,
providing valuable information about brain activity either
during hallucinations or at rest. Studies on AVHs mainly
employ neurophysiological methods (i.e., EEG), functional
magnetic resonance imaging (fMRI), and, recently, transcra-
nial magnetic stimulation (TMS). Most EEG studies showed
changes in activity in the left superior temporal gyrus [15–18],
not surprisingly since the involvement of this area in auditory
processing. fMRI studies contributedmuch to understanding
brain activity in AVHs: Allen and colleagues [19] proposed
a neuroanatomical model of hallucinations including brain
areas involved in linguistic processing, attention, memory,
and emotion. In particular regarding AVHs, they hypothe-
sized an altered connectivity between the superior temporal,
inferior frontal gyrus and anterior cingulate cortex thatmight
cause dysfunctional activation in language processing areas.
Grounding upon the contribution of Hoffman et al. [20], the
authors also hypothesized an increased activation or hyper-
coupling of speech production centers in the inferior frontal
cortex and speech perception areas in left temporoparietal
cortex. These areas seem to be specifically involved in the
pathophysiology of AVHs, yet themodel includes other brain
regions such as Broca’s area, the dorsolateral prefrontal cortex
(DLPFC), orbitofrontal cortex (OFC), the supplementary
motor area (SMA), the dorsal and ventral anterior cingulate
(DaC; VaC), the cerebellum, and a number of subcortical
regions (Figure 1).
Recent contributions are divided into “state” studies
(which investigated brain areas involved during AVH expe-
rience) and “trait” studies (which investigate the tendency
to hallucinate) [21]. State studies highlighted the role of
areas related to inner speech production such as the bilateral
inferior frontal gyrus (IFG) and the bilateral postcentral
gyrus, plus the left inferior parietal lobe (IPL) that could play
a role in the misattribution of the speech as not being self-
generated. On the other hand, trait studies focused on areas
associated with speech perception such as the left superior
temporal gyrus (STG) and leftmiddle temporal gyrus (MTG)
and anterior cingulate cortex (ACC) that could similar to left
IPL play a role in the distorted self-monitoring of speech [22].
An involvement is also shown for putamen and Wernicke’s
areas and its right homologue [23].
In conclusion, studies suggest that the core mechanisms
of AVHs involve a complex functional loop including several
brain areas interconnected, rather than a single pathway [23].
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Figure 1: A neuroanatomical model of the hallucinating brain [19].
4. Auditory Verbal Hallucinations (AVH) in
Other Disorders
Though the high prevalence in schizophrenia (40%–80%;
[24]), AVHs are not specific for the disorder and, likewise,
occur in the 10%–15% of nonclinical subjects [25, 26]. In
healthy subjects, the presence of AVHs is frequently associ-
ated with subclinical levels of other schizotypal phenomena,
plus an increased family loading for psychosis and axis I
disorders and a higher prevalence of childhood trauma,
but these subjects do not meet the criteria for schizoty-
pal, schizoid, or paranoid disorders [27]. Furthermore, a
crucial difference between the emotional content of AVHs
in healthy individuals and patients with schizophrenia has
been observed [28, 29]: while in schizophrenia AVHs are
characterized by a negative emotional content leading to
perceived distress and to a lower global functioning, voices of
the healthy subjects mainly have a positive emotional content
and are often not disturbing.This difference in the emotional
content could distinguish between benign hallucinations and
psychopathology.
In regard to clinical conditions, AVHs are frequently
found in neurological or neurodegenerative disorders such
as Alzheimer’s disease, Parkinson’s disease, dementia, hearing
impairment and epilepsy [13, 30, 31], substance abuse [32],
and in psychiatric conditions such as dissociative disorders,
mood disorders, and borderline personality disorder [14,
33, 34]. In particular focusing on dementia, the presenceof
behavioral symptoms (mostly delusions and hallucinations)
is significant, in particular in Alzheimer’s disease and
vascular dementia [35]: specifically, the prevalence of AVHs
ranges between 1% and 29% [13]. Hallucinations seem to
slightly increase correlating with the severity of dementia on
the Clinical Dementia Rating [35], with greater percentage
(21%) in moderate dementia. Findings also showed that
psychotic symptoms in dementia frequently lead to caregiver
distress and, consequently, to institutionalization and greater
cognitive deterioration [13, 14].
5. Case Presentation
A seventy-six-years-old woman presented with her daughter
to the Institute, complaining of hearing disturbing voices
(AVHs according to Neuropsychiatric Inventory Clinician
(NPI-C; [36]) started on August 2012. She reported she
firstly suffered from hypnagogic hallucinations represented
by religious choirs which later turned into hearing her dead
newborn son’s voice. These AVHs initially had a positive
content, while afterwards she began to hear threatening
voices associated with sleep disturbances. On presentation,
she also reported fear of the dark and being left alone at home.
A partial awareness of the hallucinating origin of the voices,
typical in hallucinosis, distinguished her clinical picture from
AVHs in psychosis. Her insight could be assessed through the
Schedule for theAssessment of Insight (SAI; [37]): thewoman
showed quite high insight with regard to the recognition
of her abnormal mental events and actively searched for
treatment, accepting therapy with good adherence.
Magnetic resonance images showed bilaterally altered
areas characterizing the periventricular and subcortical su-
pratentorial white matter, in conjunction with vascular-de-
generative subcortical encephalopathy features. The woman’s
cognitive clinical picture was a Mild Cognitive Impairment,
though the long-term duration and the clinical evidence of
progression set the diagnosis of dementia.
The pharmacological treatment essentially consisted of
risperidone, gradually decreased. However, AVHs has been
shown to be particularly difficult-to-treat and resistant to
pharmacotherapy, suggesting that the improvement reached
was not attributable to pharmacological treatment.
On presentation, her cognitive function was assessed
through the Mini Mental State Examination (MMSE; [38])
reaching a score of 25.24; the Symptoms Check-List 90-R
(SCL 90-R; [39]) was also administered, showing high values
on “obsessivity compulsivity” (40%), “depression” (37%), and
“psychoticism” (50%) areas. The intensity and features of the
auditory verbal hallucinations were assessed during a psychi-
atric interview,with the aid of theNeuropsychiatric Inventory
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Clinician (NPI-C; [36]). This instrument represents a com-
prehensive assessment tool for neuropsychiatric symptoms
and psychopathology in Alzheimer’s disease and other neu-
rodegenerative disorders. The main results showed neither
delusions nor agitation, irritability, aggression, disinhibition
or aberrant motor and verbal disturbances. Conversely, as
previously mentioned, the patient complained about daily
threatening voices which caused her sleep disturbances and,
consequently, significant distress.
The woman was submitted to a 10Hz rTMS treatment
over T3P3 (temporoparietal cortex) at 80% motor threshold.
The protocol of administration consisted in a 15-day daily
treatment, with a stimulation sequence of 13 trains of 200
stimuli each (50 seconds intertrain interval), for an amount of
2600 stimuli. After treatment, the patient reported a marked
reduction in AVHs: their frequency drastically decreased,
their content loss threatening features, and, consequently, the
associated distress considerably lowered. Also, no side effects
were reported during all treatment and in the aftermath.
6. Discussion
Previous studies regarding the use of TMS in the treatment
of AVHs mostly employed the low-frequency rTMS protocol
firstly proposed by Hoffman and colleagues [4]. Yet, to date,
most literature concerning the employ of TMS in AVHs
focused for the most part on schizophrenic patients, which
have considerably different traits compared to elderly people
with neurodegenerative disorders. In addition, the absence of
delusional features in hallucinations set the patient’s clinical
picture markedly distant from psychosis: AVHs were not
embedded in a delusional frame and not related to any
particular delusional belief. Moreover, a partial awareness
was preserved, almost giving the woman’s AVHs the fea-
tures of hallucinosis. This, in addition to neurodegenerative
phenomena highlighted by MRI, explains our choice for
a high frequency rTMS protocol. Given the evidence of
links interruptions between strategic temporal and frontal
brain regions [40], we hypothesized different features of
AVHs between schizophrenia and dementia. In particular,
we supposed the primary role of a disconnective syndrome
rather than cortical hyperactivity [41–43] in dementia: this
explains our choice of the rTMS protocol mentioned above.
On the other hand, as far as we know, the literature
concerning AVHs in elderly people did not contemplate the
employ of TMS as a therapeutic tool. Hence, this contribu-
tion sets in a promising field of extending the therapeutic
purposes of TMS: this latter proves as potentially useful
also in some difficult-to-treat neurodegenerative disorders
symptoms, such as behavioral symptoms. Currently, no
specific therapeutic guidelines are available for behavioral
symptoms, in particular for pharmacoresistant AVHs: TMS
could represent a valuable treatment because of its effect
on multiple symptoms. In particular, AVHs improvement
is associated with mood and cognitive improvement: we
actually cannot establish a causative connection affirming
which is the primary target of rTMS treatment, but, as far as
we know, we can observe its effects both onAVHs,mood, and
cognition.Though further research is needed, this represents
a first, encouraging result: next step could be an analysis of
changes in functional andmetabolic brain activity after rTMS
treatment.
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